Background
Acinetobacter baumannii complex (
A. baumannii complex) is a group of closely related, ubiquitous, Gram-negative coccobacilli of the
Acinetobacter genus. It includes
Acinetobacter baumannii, Acinetobacter pittii, Acinetobacter nosocomialis and
Acinetobacter calcoaceticus [
1,
2]. Among the 60 known
Acinetobacter species [
3], pathogens of the
A. baumannii complex are the most clinically relevant [
4] since they cause a number of diseases, such as hospital- and community-acquired pneumonia and bloodstream, skin and soft tissue, and urinary tract infections [
4].
A. baumannii complex received a lot of public attention in the United States in particular, since these pathogens were highly prevalent in infections amongst military staff based in Iraq between 2003 and 2005 [
5,
6]. Due to their environmental persistence [
7‐
9], species of the
A. baumannii complex are particularly known as frequent causes of healthcare-associated infections, especially in intensive care units (ICUs) [
10‐
12].
Members of the
A. baumannii complex have developed both intrinsic and acquired resistance against many common antibiotics, such as penicillins, cephalosporins and aminoglycosides. Therefore, carbapenems have become important treatment options for infections with
A. baumannii complex [
13]. However, after they have been increasingly reported since the early 1990s [
14‐
17], carbapenem-resistant
A. baumannii complex species have emerged worldwide over the last decades [
18‐
20]. Carbapenem-resistant
A. baumannii sensu stricto have been shown to be significantly associated with increased mortality [
21] and prolonged hospital stays [
22]. A recent study by Cassini et al. [
23] estimated that approximately 27,000 infections and 2300 deaths in 2015 were caused by carbapenem-resistant
Acinetobacter species in countries in the European Union and European Economic Area. The World Health Organization (WHO) and the Centre for Disease Control (CDC) both separately ranked carbapenem-resistant
A. baumannii as a high priority antibiotic-resistant pathogen [
24,
25].
According to the European Antimicrobial Resistance Surveillance Network (EARS-Net), carbapenem resistance in
Acinetobacter species from invasive infections in Germany varied between 6.5% in 2016 and 4.4% in 2018 [
26]. However, there is a lack of studies that systematically investigate the current national epidemiology of carbapenem resistance in species of the
A. baumannii complex. This study therefore aims to provide a comprehensive analysis of epidemiological trends of carbapenem-resistant
Acinetobacter baumannii complex (CRABC) in Germany and seeks to identify possible risk factors that are associated with this resistance.
A. baumannii complex was analysed, instead of
A. baumannii sensu stricto, because treatment decisions are often based on
A. baumannii complex infection diagnoses, as a result of many laboratories not differentiating
A. baumannii complex by species level in routine microbiological diagnostics.
Methods
Outcomes, study design and the German Antibiotic Resistance Surveillance system
The primary outcome is the proportion of carbapenem-resistant
A. baumannii complex isolates among all
A. baumannii complex isolates tested for carbapenem resistance. Additionally, we analysed factors that are associated with the likelihood of carbapenem resistance in
A. baumannii complex isolates (see “
Study variables” section below).
The secondary outcomes of interest are (1) the proportion of carbapenem-resistant non-baumannii complex Acinetobacter isolates among all non-baumannii complex Acinetobacter isolates tested for carbapenem resistance and (2) the proportional distribution of A. baumannii complex species among all Acinetobacter species in different clinical specimen materials.
We performed a retrospective observational study using data from the German
Antibiotic Resistance Surveillance (ARS) system between 2014 and 2018. Laboratories that voluntarily participate in the surveillance system submit routine clinical microbiological data to the Robert Koch Institute (RKI) [
27]. These data include results from pathogen identification and antimicrobial susceptibility testing, as well as pseudonymised information on health care facilities and patient characteristics, such as care setting type, hospital ward, age, gender, specimen materials and the geographical location of patient care [
28]. Forty-eight laboratories contributed to the ARS system in 2018, which includes data from around 13% of all hospitals (389 out of ~ 3000) and around 16% of all outpatient clinics (16,016 out of ~ 100,000) in Germany [
29].
Selection of Acinetobacter isolates
Isolates obtained between 2014 and 2018 were selected for the primary analysis. We avoided including multiple isolates from individual patients’ single infection episodes by selecting only the patients’ first isolate per specimen and per quarter. Since this analysis focuses on clinical infections, isolates derived for multidrug-resistant pathogen screening were also excluded.
For the main analysis, we included all
Acinetobacter species isolates that are part of the
A. baumannii complex (i.e.
A. baumannii,
A. pittii,
A. calcoaceticus and
A. nosocomalis). In addition, we only selected isolates that were tested against at least one of the following carbapenems: meropenem, imipenem, and doripenem. Ertapenem was not selected since it has a considerably different pharmacology compared to the selected carbapenems [
30]. We defined an isolate as carbapenem-resistant if it was tested as “resistant” (R) to at least one of the carbapenems of interest based on the standards used in the participating laboratories, such as the guidelines of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) or the Clinical and Laboratory Standards Institute (CLSI). In order to determine proportions of carbapenem resistance among non-baumannii complex
Acinetobacter species, isolates from the respective species were included but the same selection criteria were otherwise used as described above.
For the analysis of the proportional distribution of A. baumannii complex and non-baumannii complex Acinetobacter species, only isolates that were identified at species level were included. Since complete species identification results were increasingly available after 2014, we only selected isolates from 2015 to 2018 for this analysis. In this analysis, we also included isolates without carbapenem testing.
Study variables
Carbapenem resistance was analysed for the following variables: care setting type, year of sampling, region in Germany, age, gender and, clinical specimen materials. We grouped care setting type into the following categories: outpatient clinics (primary healthcare facilities), secondary care hospitals (offering basic and standard care), tertiary care hospitals (offering maximum care, such as university hospitals), specialist care hospitals (offering specialised care or private hospitals), prevention and rehabilitation care centres, and other hospitals (offering psychiatric, neurological and/or geriatric care only). Clinical specimen materials were categorised into the following groups: wound (swabs from wounds and abscesses), blood (blood cultures), urine (urine samples), upper respiratory materials (swabs from the upper respiratory tract), lower respiratory materials (bronchial lavage, bronchial secretion, bronchial rinse water, sputum and tracheal secretion), and other specimens that did not fit in the categories listed above (i.e. swabs, biopsy tissues, dialysate material, ejaculate, skin flakes, hair and nails, catheter, cerebrospinal fluid, puncture material, stool samples and non-specified materials). We grouped patient gender into female and male and categorised patient ages in six different groups (< 1, 1–19, 20–39, 40–59, 60–79, ≥ 80 years). Furthermore, to determine the isolate’s geographical origin (location of the healthcare facility), each of the federal states was categorised into one of five major regions in Germany: Northeast (Mecklenburg-West Pomerania, Brandenburg, Berlin, Saxony-Anhalt), Southeast (Bavaria, Saxony, Thuringia), Southwest (Hesse, Rhineland-Palatinate, Saarland, Baden-Wurttemberg), West (North Rhine-Westphalia) and Northwest (Bremen, Lower Saxony, Hamburg, Schleswig–Holstein). We considered all variables as categorical for statistical analyses, apart from year, which was treated as a continuous variable.
Statistical analyses
All statistical analyses were performed using R version 3.6.1 [
31] and the “survey” package (version 3.37) [
32]. We used percentages with 95% confidence intervals (95% CI) to describe proportions of carbapenem-resistant isolates among all isolates tested against carbapenems. Univariable and multivariable logistic regression models were performed to identify patient and healthcare-related risk factors that are associated with carbapenem resistance in isolates from patients with
A. baumannii complex infections. All previously listed variables were included in the univariable and the multivariable logistic regression model. We accounted for clustering at facility level in the carbapenem resistance proportions calculations and the analysis of associations between carbapenem resistance and the selected variables.
Discussion
Carbapenem resistance in
A. baumannii complex isolates from hospitalised patients in Germany was 4.4% in 2018, which is significantly lower than those recently observed in hospitals in other regions across the world such as North America (44%) [
18], Latin American (50–90%) [
18,
33,
34] and the Asia–Pacific region (79%) [
18]. In China and Saudi Arabia, 71.0% and 60.0% of
Acinetobacter isolates from hospitalised patients were found to be carbapenem-resistant, respectively [
35,
36].
Similar to the situation in Germany described in this study, Norway, Slovenia, and Portugal also reported decreasing carbapenem resistance in
Acinetobacter species [
26]. In the United States, the number of estimated cases among hospitalised patients infected with carbapenem-resistant
A. baumannii declined from 11,700 to 8500 between 2012 and 2017 [
25]. However, rising carbapenem resistance among
Acinetobacter species were observed in other countries, such as the Czech Republic, Slovakia, Croatia [
26] and China [
35], highlighting its persisting clinical significance and importance of continuous surveillance. One possible reason for a declining trend in some countries, such as in Norway, Slovenia and the USA, is their adoption of national strategies in recent years with established targets to reduce antibiotic consumption, which is not the case for Slovakia and Croatia [
37]. In Germany, the German
Antibiotic Resistance Strategy includes several measures to limit antibiotic resistance, such as training courses in antibiotic stewardship as well as the implementation and promotion of surveillance systems [
38].
Despite the decreasing trends found in our study, the analysis also revealed that proportions of CRABC are higher in German hospitals compared to outpatient clinics. Carbapenems are reserve antibiotics with a broad activity spectrum and are mainly used in hospitalised patients with serious illnesses such as sepsis or lower respiratory tract infections [
39]. Several previous studies have found that the use of carbapenems is correlated with carbapenem resistance in hospitals [
40‐
43]. In Germany, it has been shown that an increase in the use of carbapenems was associated with a rise in carbapenem resistance in
A. baumannii in ICUs between 2001 and 2015 [
44]. Another possible reason for higher proportions of CRABC in hospitals is the higher number of co-morbidities of hospitalised patients, which are associated with antibiotic resistance, compared to patients in outpatient clinics [
45].
Our data also indicate regional differences in CRABC proportions in Germany: In the North-western and Western regions, significantly higher proportions of resistance were observed than in the other regions in Germany. These differences were mainly observed in isolates from hospitals. One possible explanation for this might be regional differences in hospital usage of carbapenems. However, this has not yet been evidenced in any publications. Although there are national guidelines for the management of infections/colonisation with multi-resistant Gram-negative rods, including
Acinetobacter [
46], the implementation of infection prevention and control and antibiotic stewardship strategies are regulated differently by the 16 federal states and between hospitals, which may also contribute to the regional differences. Interestingly, large regional differences in carbapenem resistance in
Acinetobacter isolates have also been observed at the European level, where resistance proportions are particularly high in Southern and Eastern European countries [
26,
47]. This might be explained by the implementation of antibiotic stewardship programmes and strategies for infection prevention and control in some areas, which are effective against carbapenem-resistant
A. baumannii infections and other pathogens [
25,
48,
49]. Regional CRABC proportions might also be influenced by local CRABC hospital outbreaks and spreads of CRABC strains. However, the reasons for the observed regional differences should be investigated in further studies that assess potential risk factors among hospital patients, such as previous carbapenem exposure and stays in countries with a high prevalence of carbapenem resistance.
We also observed that carbapenem resistance is more likely to be found in
A. baumannii complex isolates from patients between 20 and 70 years than in isolates from children, adolescents and patients who are 80 years or older. Similarly, there was also a higher likelihood of resistance in middle aged adults and elderly patients in other pathogens, including carbapenem-resistant
Enterobacteriaceae [
50], carbapenem non-susceptible
Klebsiella pneumoniea [
51] and vancomycin-resistant
Enterococcus faecium [
52,
53]. Older patients are more likely to be affected by antimicrobial resistance since the probability of being colonised or infected with resistant pathogens increases with each exposure to antibiotics over the course of their lifetime. However, why the very elderly (≥ 80 years) show profoundly less carbapenem resistance proportions remains unclear and could be addressed in further studies. Interestingly, our data identified clear differences between men and women in CRABC proportions in adults aged 20 to 39. In this age group, carbapenem resistance in
A. baumannii complex isolates from men were significantly higher than in isolates from women (14.6% vs. 2.5%). A similar observation has already been described for carbapenem-non-susceptible
Klebsiella pneumoniae in Germany, although the reasons for this observation remain unknown [
51]. Studies have suggested that hormonal differences in this age group may be responsible for immune advantages against infectious diseases amongst women [
54]. However, whether this explains the observed gender distribution of antibiotic resistant infections is unknown and should be addressed in further studies.
Furthermore, our study revealed high proportions of CRABC in blood isolates (8.1%) and lower respiratory materials (11.4%). Higher proportions of resistance in blood isolates (7.6%) in comparison to other clinical specimen materials have also been reported in multidrug-resistant
A. baumannii isolates among hospitalised patients in Germany between 2002 and 2006 [
55]. Blood isolates and lower respiratory materials most likely represent more severe diseases, such as bloodstream infections and pneumonia which often require fast empirical antibiotic therapies. Hence, increased carbapenem resistance limits the therapeutic effectiveness of empirical carbapenem treatment in those patients.
Our study also revealed that in all clinical specimen materials,
A. baumannii sensu stricto accounted for 65% of all
A. baumannii complex species, which is much lower than the commonly-assumed proportion of over 90% in Europe [
56]. In line with our findings, a study from France showed that only 40% of all
A. baumannii complex bloodstream infections were associated with
A. baumannii sensu stricto [
57]. Interestingly, our data also indicate that species of the
A. baumannii complex only accounted for 60% of all isolated
Acinetobacter species.
A. baumannii complex proportions were even lower (44%) in
Acinetobacter bloodstream isolates. Similar results were also found in a study from Japan, where
A. baumannii complex species accounted for 52% of all
Acinetobacter isolates identified in patients with bacteraemia [
58]. In contrast, other studies have shown that
A. baumannii complex species are the predominant species in clinical
Acinetobacter bloodstream infections [
59,
60]. These conflicting results indicate that
Acinetobacter species distribution may be locally very different.
Our finding of substantial differences in carbapenem resistance proportions among the different Acinetobacter species suggests that estimates for carbapenem resistance in clinical Acinetobacter isolates are largely dependent on the proportion of individual A. baumannii complex and non-baumannii complex Acinetobacter species. As a result, our study emphasises the importance of identifying Acinetobacter isolates with associated carbapenem resistances at the species level in order to fully understand the extent of carbapenem resistance in Acinetobacter infections.
Strengths and limitations
To our knowledge, this study is the most comprehensive analysis of the current epidemiology and risk factors of carbapenem resistance in A. baumannii complex isolates in Germany. Based on data from the German ARS system, we analysed almost 44,000 clinical A. baumannii complex isolates from more than 39,000 patient visits in hospitals and outpatient clinics.
Our study is also subject to several limitations. Firstly, since no information on diagnoses is available in the ARS database, it can only be assumed that the clinical specimens represent infectious diseases. Although we excluded all isolates labelled as screening samples, it is also possible that some of the included isolates (e.g. swabs of upper respiratory materials) actually represent screening samples that were not assigned as such by the hospital or laboratory [
51]. Secondly, because participation in the ARS system is voluntary, the coverage of healthcare facilities providing ARS data may differs across regions and may not be representative. However, numbers of isolates from the analysed German regions roughly reflect population sizes in these regions. Finally, no clinical information is available in the ARS system, such as use of medical devices and co-morbidities, which are known to be associated with carbapenem resistance in
A. baumannii complex infections.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.